Dihexa is an oligopeptide drug derived from angiotensin IV that binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at the c-Met receptor. In assays of neurotrophic activity, Dihexa has been found to be seven orders of magnitude more potent than brain-derived neurotrophic factor (BDNF), with demonstrated improvements in cognitive function in animal models of Alzheimer’s disease-like impairment. It is orally active and blood-brain barrier permeable.

What is Dihexa?

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small oligopeptide drug developed from angiotensin IV, a naturally occurring peptide with roles in learning, memory, and blood flow regulation. It binds with high affinity to hepatocyte growth factor (HGF) and amplifies HGF’s activity at its receptor, c-Met. c-Met signaling plays a key role in neuronal survival, synaptic plasticity, and cognitive function. Dihexa was developed specifically to be orally active and capable of crossing the blood-brain barrier, making it a practical candidate for neurological applications. It has shown potent pro-cognitive effects in animal models of Alzheimer’s disease-like cognitive impairment.

How does Dihexa work?

Dihexa binds to HGF and potentiates its activity at the c-Met receptor on neurons. This amplification of HGF/c-Met signaling promotes the formation of new synaptic connections between neurons, a process critical for learning, memory formation, and cognitive resilience. In assays measuring neurotrophic activity, Dihexa demonstrated potency seven orders of magnitude greater than BDNF, one of the brain’s primary growth factors. This exceptional potency translates to pronounced improvements in synaptic connectivity in preclinical models. Because Dihexa is both orally bioavailable and capable of crossing the blood-brain barrier, it can reach the central nervous system through routes that are practical for clinical use.

Clinically observed benefits of Dihexa

• Improves cognitive function: Dihexa has produced potent improvements in cognitive performance in animal models of Alzheimer’s disease-like impairment.
• Helps in the treatment of Alzheimer’s disease and Parkinson’s disease: Its mechanism of promoting synaptic connectivity and neuronal survival makes it a candidate for neurodegenerative disease applications.
• Improves long and short-term memory: By enhancing synaptic plasticity and connectivity, Dihexa supports the neural architecture underlying memory encoding and retrieval.
• Helps manage depression: Dihexa’s neurotrophic activity extends to mood-regulating circuits and neuroplasticity pathways associated with depression.
• Enhances creative thinking and social interaction: Improved synaptic function and cognitive clarity support higher-order cognitive processes.
• Improved heart health: HGF/c-Met signaling has roles beyond the brain, including cardiovascular tissue — a secondary area of observed benefit.
• Improves brain focus: Enhanced synaptic transmission and neuroplasticity support sustained attention and mental clarity.

How is Dihexa administered?

Dihexa is available in the following compounding formats:

• Capsule — oral delivery, leveraging Dihexa’s oral bioavailability
• Topical — transdermal application for systemic delivery

Frequently asked questions about Dihexa

Q: How does Dihexa compare to BDNF in potency?

A: In neurotrophic activity assays, Dihexa has been found to be seven orders of magnitude more potent than brain-derived neurotrophic factor (BDNF). BDNF is one of the brain’s primary endogenous growth factors, making this a significant benchmark for Dihexa’s neurological activity.

Q: Is Dihexa safe for long-term use?

A: The current body of research on Dihexa is primarily preclinical. Its development has focused on Alzheimer’s disease and other disorders that would benefit from augmented synaptic connectivity. Long-term human safety data are not yet established; use should occur under physician supervision with ongoing monitoring.

Q: Does Dihexa work the same way as conventional nootropics or stimulants?

A: No. Dihexa operates through HGF/c-Met receptor potentiation, a mechanism that promotes structural synaptic changes and neuroplasticity. This is distinct from stimulants or acetylcholinesterase inhibitors, which modulate neurotransmitter availability rather than synaptic architecture.

Clinical research

Research published in the Journal of Pharmacology and Experimental Therapeutics (McCoy et al., 2013) evaluated metabolically stabilized angiotensin IV analogs, including Dihexa, as pro-cognitive and anti-dementia agents, demonstrating meaningful cognitive improvements in animal models. The foundational patent work by Harding et al. (US Patent 8598118) characterized hepatocyte growth factor mimics as therapeutic agents and established the mechanistic basis for Dihexa’s development. Peer-reviewed research supports its application in cognitive enhancement and neurodegenerative disease contexts.

[Related: See our full Peptide Therapy Series]

These statements have not been evaluated by the Food and Drug Administration. These compounds are not intended to diagnose, treat, cure, or prevent any disease. This content is for informational purposes only and does not constitute medical advice. Peptide therapy should only be pursued under the supervision of a licensed physician.